Teva Strategy and Business Model

Executive Overview

Teva is a global pharmaceutical company whose strategy combines a very large generics platform with a more focused innovative-medicines portfolio. Founded in 1901 and headquartered in Tel Aviv, Israel, Teva is best known for scale in generic medicines, but its current strategy under the company’s “Pivot to Growth” plan is to rely less over time on commodity-like volume and more on differentiated products such as AUSTEDO, AJOVY, and UZEDY, plus complex generics, biosimilars, and selected partnered pipeline assets. Teva reports through four segments: United States, Europe, International Markets, and Active Pharmaceutical Ingredients (API). Its internal API business, TAPI, matters strategically because it supports supply security and also sells to third parties. The economics of Teva’s portfolio are mixed by design: generics create scale, customer access, and cash flow, while innovative medicines and complex products offer better margin potential and more durable growth. The company has also spent several years deleveraging after the 2016 Actavis Generics acquisition and repositioning after loss of exclusivity on major legacy products. Teva reported $15.8 billion of revenue in FY2023.

Teva at a Glance

Logo
Common name	Teva
Full legal name	Teva Pharmaceutical Industries Limited
Headquarters	Tel Aviv, Israel
Ownership	Public company; no controlling shareholder publicly disclosed
Ticker	TEVA
Exchange	NYSE - New York Stock Exchange
Market Cap	$37.92B
Revenue (FY2024)	$16.54B
Founding / major historical milestones	Founded in 1901; expanded through Sicor (2004), Ivax (2006), Barr (2008), Cephalon (2011), and Actavis Generics (2016); launched “Pivot to Growth” strategy in 2023
Industry or industries	Pharmaceuticals; generic medicines; specialty / branded pharmaceuticals; active pharmaceutical ingredients
Key products or services	Generic medicines; AUSTEDO; AJOVY; UZEDY; biosimilars; active pharmaceutical ingredients through TAPI
Geographic footprint	Global, with major operations in the United States, Europe, Israel, and broader international markets
Business segments as officially reported	United States; Europe; International Markets; Active Pharmaceutical Ingredients
Company website	https://www.tevapharm.com

1. What Is the Strategy of Teva?

Teva’s public strategy, especially since the 2023 launch of its “Pivot to Growth” plan under CEO Richard Francis, is best understood as a hybrid pharmaceutical model: preserve the scale and cash generation of a global generics franchise while increasing the weight of higher-margin innovative and complex products.

1. 1a. What is the winning aspiration of Teva?

   Teva’s winning aspiration is to move from a turnaround story back to sustainable, profitable growth. In practical terms, winning means making Teva less dependent on aging legacy products and undifferentiated generic price competition, while increasing the contribution of growth brands such as AUSTEDO, AJOVY, and UZEDY. Management’s public framing through 2023 and 2024 emphasized growth through the second half of the decade, better profitability, stronger cash generation, and continued deleveraging after the Actavis Generics acquisition.

2. 1b. Where does Teva play?

   Teva plays in three overlapping arenas. First, it competes in global generic medicines across oral solids, injectables, respiratory products, and other complex categories. Second, it competes in specialty and innovative medicines, with a current emphasis on central nervous system and related specialist categories such as movement disorders, migraine, and schizophrenia. Third, it operates in active pharmaceutical ingredients through TAPI, serving both internal manufacturing demand and third-party customers. Geographically, Teva plays globally but reports around the United States, Europe, International Markets, and API.

3. 1c. How does Teva plan to win?

   Teva’s route to winning is mix shift plus execution. In generics, it does not appear to want to compete only on lowest price; instead, it emphasizes complex generics, difficult-to-manufacture products, selected first-to-file opportunities, biosimilars, and supply reliability. In branded medicines, it aims to win through clinically differentiated products, specialist commercial execution, market access, and lifecycle management. Teva also uses partnerships to add innovation and biosimilar capability without carrying the full cost and risk of a broad internal discovery model.

4. 1d. What capabilities must Teva have in place?

   Teva needs a narrow but demanding set of capabilities: global quality and regulatory compliance; efficient large-scale manufacturing; API sourcing and vertical integration through TAPI; patent and legal execution for generic launches; specialty clinical development; medical affairs; payer access and contracting; and alliance management for partnered products. A key challenge is that Teva must run both a high-volume generics system and a focused specialty-pharma model at the same time without creating too much organizational complexity.

5. 1e. What management systems does Teva require?

   Teva needs management systems that enforce portfolio discipline and capital discipline. That includes product-by-product profitability reviews, launch readiness governance, strong quality and pharmacovigilance controls, capital allocation tied to branded growth and debt reduction, and operating metrics that balance revenue with cash flow and leverage. A geography-based reporting structure helps management see regional economics, while centralized manufacturing, regulatory, and R&D processes help avoid duplication. Given Teva’s history, litigation management, compliance, and settlement execution are also core management systems rather than side issues.

2. What Are the Current Strategic Initiatives of Teva?

Based on Teva’s 2023 Investor Day materials, FY2023 annual reporting, and 2024 management commentary, the company’s current strategic initiatives cluster around a few concrete priorities rather than a broad transformation agenda.

• Scale the three main growth brands. Teva has made AUSTEDO, AJOVY, and UZEDY the commercial core of its near-term growth plan. AUSTEDO is central in tardive dyskinesia and Huntington’s disease; AJOVY is Teva’s migraine prevention brand; and UZEDY is the company’s newer long-acting injectable for schizophrenia, launched in the United States after its 2023 approval.
• Step up innovation through focused pipeline investment and business development. Teva has signaled that it does not intend to spread R&D across too many therapy areas. Instead, it is concentrating on selected areas where it believes it can build differentiated assets, while supplementing internal development with partnerships such as the Sanofi collaboration around duvakitug in inflammatory bowel disease.
• Sustain the generics powerhouse while improving portfolio quality. Teva’s strategy is not simply “more generics.” The company has emphasized complex generics, respiratory products, injectables, and selected launches where manufacturing, regulatory, or legal complexity can produce better economics than commodity oral solids.
• Expand biosimilars through partnerships. Rather than build every capability organically, Teva has used alliances, including with Alvotech, to broaden its biosimilar portfolio. This allows Teva to use its commercial reach while sharing development risk and capital intensity.
• Focus the business and simplify the portfolio. Management has described a need to sharpen the portfolio, reduce distractions, and allocate resources to products and markets that can earn acceptable returns. That has implications for SKU rationalization, geographic prioritization, and operating-model simplification.
• Continue deleveraging and strengthen the balance sheet. Teva’s debt burden from the 2016 Actavis Generics acquisition has shaped capital allocation for years. Further debt reduction, cash generation, and disciplined reinvestment remain strategic priorities because they determine how much flexibility Teva has for launches, R&D, and external deals.

3. What Is the Business Model of Teva?

• What customers actually buy: Teva sells finished pharmaceutical products and APIs. Customers buy generic medicines, branded specialty medicines, biosimilars, and ingredient supply through TAPI. In generics, customers are largely buying regulatory equivalence, availability, and price. In branded products, they are buying differentiated clinical outcomes supported by market access and specialist promotion.
• Recurring or repeat-driven versus one-time: Teva’s model is largely repeat-driven rather than one-time. Chronic medicines are refilled over long periods, hospitals and pharmacies reorder continuously, and tender markets recur. Even though each sale is unit-based, the underlying demand is often recurring.
• How pricing power works: Pricing power differs sharply by product class. Commodity generics usually have weak pricing power because multiple suppliers compete and buyers are concentrated. Pricing is better in complex generics, shortage-sensitive categories, and difficult-to-make products. Branded products can support stronger pricing before loss of exclusivity, but payer negotiations and rebate pressure still matter.
• Why the business mix matters: Mix is central to Teva’s economics. Generics provide scale, cash flow, manufacturing utilization, and customer reach, but they are exposed to price erosion. Innovative medicines and some complex products contribute more margin and strategic value. That is why Teva’s strategy focuses so heavily on growing branded and complex-product revenue within a still-large generics base.
• What drives gross margin, operating margin, and cash generation: Gross margin is shaped by product mix, manufacturing efficiency, API sourcing, competitive intensity, and supply reliability. Operating margin depends additionally on R&D spend, commercial spend for specialty launches, and legal or restructuring costs. Cash generation depends on EBITDA quality, working capital discipline, capital expenditure, and litigation-related cash uses.
• Revenue model: Teva is not a subscription business. It is a unit-sales pharmaceutical model with recurring replenishment. Revenue comes from product sales to wholesalers, distributors, pharmacies, hospitals, government tender systems, and third-party pharma manufacturers that buy APIs.

4. What Products and/or Services Does Teva Sell?

Teva sells a broad portfolio of pharmaceutical products, but the strategic importance of those products is uneven.

• Generic medicines: This remains the company’s largest broad product category. Teva markets a wide range of generic oral solids, injectables, respiratory products, and other formulations across the United States, Europe, and international markets. Generics remain foundational to revenue scale and manufacturing utilization.
• Innovative medicines: Teva’s most important branded growth products as of 2024 were AUSTEDO, AJOVY, and UZEDY. These products matter disproportionately because they are more central to future growth and margin expansion than the average generic SKU.
• Legacy branded products: Teva still has legacy branded assets such as Copaxone, but these are more important historically than as the core of the forward strategy. The strategic emphasis has shifted toward newer growth brands.
• Biosimilars: Teva is building a biosimilars business through partnerships rather than relying only on fully internal development. This category is strategically important because it sits between traditional generics and specialty biologics in both complexity and margin potential.
• Active pharmaceutical ingredients: Through TAPI, Teva manufactures APIs for internal use and for sale to third-party pharmaceutical customers. This business supports both supply resilience and external revenue.

From a strategic standpoint, generic medicines still provide breadth and cash generation, but AUSTEDO, AJOVY, UZEDY, complex generics, and selected biosimilars appear more important to future profit growth.

5. What Are the Key Competitors or Peers of Teva?

Competition is product-specific. Few companies compete with Teva across both global generics and branded central nervous system products, so the best way to think about peers is by category.

• Sandoz: One of the closest large-scale global peers in generics and biosimilars.
• Viatris: A major off-patent and generic pharmaceutical competitor with broad global reach.
• Hikma Pharmaceuticals: An important competitor in injectables, generics, and selected branded markets in the Middle East and North Africa.
• Dr. Reddy’s Laboratories: A major generic and API competitor with significant U.S. exposure.
• Sun Pharmaceutical Industries: A large Indian pharmaceutical company with both specialty and generic businesses.
• Amneal Pharmaceuticals: A meaningful competitor in U.S. generics, injectables, and newer specialty categories.
• Neurocrine Biosciences: A direct branded competitor in movement disorders through INGREZZA, which competes with AUSTEDO in tardive dyskinesia.
• Eli Lilly: A competitor in migraine prevention through EMGALITY and a much larger branded pharma benchmark in specialty commercialization.
• Johnson & Johnson: A competitor in schizophrenia and long-acting injectable antipsychotics through its neuroscience portfolio.

Teva’s hybrid model means its true competitive set changes by product. In generics, scale, manufacturing, and portfolio breadth matter. In specialty medicines, clinical differentiation, payer access, and field execution matter more.

6. What Is the Marketing Strategy of Teva?

Teva’s marketing strategy differs sharply between its generic portfolio and its innovative medicines.

• In generics, marketing is mostly commercial execution rather than brand building. The emphasis is on contracting, tender participation, product availability, launch timing, customer relationships, and supply reliability. Buyers in this part of the business care more about price, service level, and breadth of portfolio than consumer-facing promotion.
• In branded medicines, marketing is far more targeted and specialist-led. Teva uses field teams, medical affairs, payer-access work, patient support services, and specialist education for products such as AUSTEDO, AJOVY, and UZEDY. The target audiences are neurologists, psychiatrists, headache specialists, movement-disorder specialists, and the payer ecosystem around them.
• Market access is a core marketing capability. In pharmaceuticals, winning formulary position and reimbursement is often as important as promotional spend. That is especially true in the United States.

Marketing is therefore a supporting capability in commodity generics but a much more important differentiator in Teva’s growth brands. The company’s strategic shift toward innovative medicines increases the relative importance of targeted specialty marketing.

7. What Are the Key Customer Segments of Teva?

• Large pharmaceutical wholesalers and distributors: In the United States, a large share of pharmaceutical volume flows through a small number of major wholesalers. This makes channel concentration strategically important.
• Retail pharmacies and chain drugstores: These customers matter heavily for generic dispensing and refill-based chronic therapies.
• Hospitals, health systems, and clinics: Particularly relevant for injectables, institutional products, and tender-driven business.
• Government and public-health purchasers: Outside the United States, many markets involve tenders or public reimbursement systems that shape volume and pricing.
• Specialty-prescribing ecosystems: For branded products, the true commercial ecosystem includes physicians, specialty pharmacies, payers, and patients, even if the physical sale flows through distribution intermediaries.
• Other pharmaceutical manufacturers: Through TAPI, Teva also serves business-to-business customers that buy APIs.

Teva is diversified by geography and product type, but it is not fully diversified by channel power: like much of the pharmaceutical industry, it deals with concentrated intermediaries in major markets.

8. What Is the Sales Model of Teva?

Teva uses multiple sales motions depending on the product category.

• Generic medicines: Sold primarily through direct account management with wholesalers, pharmacy chains, distributors, hospitals, and group purchasing structures. In many non-U.S. markets, tender processes are important.
• Branded specialty medicines: Sold through a specialist commercial model. Teva promotes to prescribers and engages payers and specialty pharmacies, while physical distribution generally still runs through wholesale and specialty channels.
• APIs: Sold through a business-to-business sales model to other pharmaceutical manufacturers.

The channel structure affects growth and pricing in different ways. Concentrated intermediaries can put pressure on generic pricing, while specialty sales forces can improve customer intimacy and launch effectiveness but increase selling expense. That is one reason Teva’s business mix matters so much to profitability.

9. In What Geographies Does Teva Operate?

Teva is a global company with reported segments in the United States, Europe, International Markets, and Active Pharmaceutical Ingredients. The United States is strategically important because it is both a large generics market and the main profit pool for Teva’s key branded products.

Europe is broad rather than concentrated in just one country, and Teva has long-standing operations across major European pharmaceutical markets. The International Markets segment includes Israel and a wider mix of markets across Latin America, Asia-Pacific, and other regions. On the operations side, Teva has manufacturing, supply, quality, regulatory, R&D, and commercial infrastructure across North America, Europe, Israel, and selected other international locations.

Teva is geographically diversified, but not all regions matter equally. The U.S. business tends to matter disproportionately for innovative products and overall earnings power, while Europe and International Markets add breadth, tender exposure, and a wider generics footprint.

10. Who Are the Owners of Teva?

Teva is a publicly traded company and, as of 2024 public filings and market data, does not have a controlling shareholder. Ownership is widely held among institutional investors. Large shareholders reported around 2024 included major asset managers such as Capital Research and Management, BlackRock, and Vanguard, subject to change over time. Teva’s securities trade publicly in both the United States and Israel.

11. How Is Teva Organized?

At the reporting level, Teva is organized primarily by geography: United States, Europe, International Markets, and Active Pharmaceutical Ingredients. That is the official external segmentation.

At a practical operating level, Teva also runs across product and capability lines. It has a global generics business, an innovative-medicines portfolio, and TAPI as the API arm. Those commercial engines are supported by centralized functions such as global operations, quality, regulatory affairs, R&D, legal, medical affairs, and corporate finance.

This means Teva is not best understood as a simple set of independent country businesses. It is a matrix of geographic P&Ls supported by shared global manufacturing, regulatory, and scientific capabilities.

12. How Does Teva Operate?

On a day-to-day basis, Teva operates as a highly regulated, portfolio-management-intensive pharmaceutical company. The core value-creating activities are:

1. Portfolio selection and planning: deciding which generic launches, branded indications, biosimilars, and geographic markets merit investment.
2. Sourcing and API production: securing raw materials and APIs, including through TAPI and external vendors.
3. Manufacturing and quality release: producing finished dosage forms under strict regulatory and quality standards.
4. Regulatory execution: filing, maintaining, and defending approvals across multiple jurisdictions.
5. Commercial execution: contracting with wholesalers and pharmacies in generics and deploying specialist field teams for branded products.
6. Lifecycle management and compliance: managing pharmacovigilance, product changes, pricing, reimbursement, and post-approval commitments.

The main operational complexities are large SKU counts, regulatory scrutiny, patent and exclusivity timing, manufacturing reliability, and the need to balance cost efficiency with uninterrupted supply. For Teva, an operational failure can mean not just lost sales but also customer erosion, regulatory exposure, or delayed launches.

13. What Are the Growth Opportunities for Teva?

• Further growth from AUSTEDO: This remains one of Teva’s most important branded opportunities because of its position in movement disorders and its significance to group profitability.
• Broader AJOVY penetration: AJOVY offers room for growth through physician adoption, payer access, and geographic expansion in migraine prevention.
• Scaling UZEDY: As a newer schizophrenia product, UZEDY represents one of Teva’s most important launch-execution opportunities.
• Biosimilars: This is a plausible medium-term growth area because Teva can combine partnerships with its commercial scale and regulatory experience.
• Complex generics and injectables: These categories can support better economics than more commoditized generic products.
• External innovation and licensing: Targeted business development can expand the pipeline without requiring Teva to rebuild a massive discovery engine.
• Margin expansion from mix and simplification: Even without explosive top-line growth, Teva can improve earnings if innovative products and complex generics become a larger share of sales and if the company keeps simplifying its portfolio and cost base.

The main constraints are generic price pressure, payer pressure in branded markets, regulatory and manufacturing risk, legal liabilities, and the need to balance growth investment against debt reduction.

14. What Is the History of Teva?

• 1901: Teva traces its roots to Jerusalem, where predecessor pharmaceutical businesses were established.
• 20th century: The company developed into a major Israeli pharmaceutical manufacturer and gradually expanded internationally.
• 2004: Teva acquired Sicor, strengthening injectables and global manufacturing capabilities.
• 2006: Teva acquired Ivax, adding scale in generics and broader international reach.
• 2008: Teva acquired Barr Pharmaceuticals, another large step in generics consolidation.
• 2011: Teva acquired Cephalon, increasing exposure to branded and specialty pharmaceuticals.
• 2016: Teva acquired Actavis Generics from Allergan. The deal expanded scale but also left the company with substantial debt.
• 2017 onward: Teva entered a prolonged period of restructuring, debt reduction, and portfolio repair as Copaxone faced generic competition and the generics market remained difficult.
• 2022: Teva entered a broad opioid settlement framework in the United States, an important milestone in addressing legacy litigation.
• 2023: Richard Francis became CEO and introduced the “Pivot to Growth” strategy, shifting the narrative from restructuring toward branded growth, innovation focus, and disciplined capital allocation.

15. What Are the Key Suppliers to Teva?

Suppliers matter materially to Teva because pharmaceuticals depend on qualified inputs, validated processes, and uninterrupted regulatory compliance.

• API and raw-material suppliers: These provide chemical intermediates, biologic materials, and other core inputs. Teva’s own TAPI business reduces some dependence here, but not all of it.
• Excipients and packaging suppliers: Standard but still strategically important because any disruption can delay production or release.
• Device and component suppliers: Relevant for inhalation products, injectables, delivery systems, and certain complex products.
• Contract development and manufacturing partners: Used where Teva does not manufacture internally or where outside capacity is strategically sensible.
• Logistics and cold-chain providers: Important for temperature-sensitive products and global distribution reliability.

Teva does not extensively disclose supplier names in its annual filings. Strategically, what matters more than any single supplier name is supplier qualification, dual sourcing where possible, regulatory reliability, and the role of TAPI in internal vertical integration.

16. What Are the Key Brands Owned by Teva?

Branding is not the main strategic lever across most of Teva’s generic portfolio, where products are usually sold by molecule and dosage form. Brand equity matters much more in the company’s innovative medicines.

• AUSTEDO: Teva’s most important growth brand in movement disorders and one of the clearest indicators of whether the company can expand branded earnings.
• AJOVY: Teva’s migraine prevention brand, positioned in a competitive but clinically important specialty category.
• UZEDY: A newer long-acting injectable for schizophrenia and one of Teva’s key launch assets.
• Copaxone: Historically one of Teva’s most important brands, though now more relevant as a legacy product than as the core growth engine.
• TAPI: The brand associated with Teva’s API business, important more in business-to-business markets than with end consumers.

In short, Teva is not a classic consumer-brand company. Its branded value is concentrated in a handful of specialty pharmaceutical assets, while its generic business competes more on price, breadth, approval status, and supply reliability.

17. How Does the Supply Chain of Teva Function?

Teva’s supply chain is strategically important because it sits at the intersection of cost, compliance, and product availability.

The chain typically begins with external raw materials and internally or externally sourced APIs. TAPI gives Teva a degree of vertical integration that many peers do not have across the same breadth of portfolio. From there, Teva formulates, manufactures, fills, packages, tests, and releases products through a global network of regulated sites. Finished goods then move through warehouses and distribution channels to wholesalers, pharmacies, hospitals, specialty pharmacies, and tender systems.

For some products, the supply chain is more complex than standard oral solids. Sterile injectables, long-acting injectables, inhalation products, biologics, and cold-chain products require tighter controls and often more specialized equipment or logistics. Supply-chain performance is therefore a strategic issue, not just an operations issue: service failures can damage customer relationships, reduce launch success, and expose the company to regulatory risk.

18. What Are the Key Assets of Teva?

• Global manufacturing network: Important for scale, product breadth, and geographic reach.
• TAPI: Teva’s API platform is both a physical asset base and a strategic capability.
• Regulatory dossiers and product registrations: For a pharma company, approved dossiers are valuable intangible assets that can be hard to replicate quickly.
• Intellectual property and know-how: Especially important in innovative medicines, complex generics, formulations, and device combinations.
• Commercial infrastructure in specialty areas: Field teams, market-access capabilities, and specialist relationships matter for AUSTEDO, AJOVY, and UZEDY.
• Partner ecosystem: Alliances in biosimilars and innovation are strategic assets because they extend Teva’s reach without requiring full in-house development of every capability.

Teva is more asset-intensive than a typical software or services company, but the key assets are both physical and intangible. Manufacturing plants matter, yet so do approvals, clinical data, formulations, and access relationships.

19. What Is the R&D Strategy of Teva?

Teva’s R&D strategy is more focused than in earlier eras. The company has signaled that it wants to invest in areas where it can realistically build differentiation rather than spread research spend across a very broad therapeutic map.

As of 2023 and 2024 communications, that has meant two things. First, Teva is prioritizing innovation in selected categories, including neuroscience and partnered immunology assets. Second, it continues to invest in complex generics, respiratory products, injectables, biosimilars, and long-acting formulations where formulation science, delivery technology, manufacturing, and regulatory know-how can create barriers to entry.

Teva’s R&D model also relies meaningfully on partnerships. That is visible in collaborations such as its work with Sanofi on duvakitug and in biosimilar alliances. The strategic logic is clear: Teva can be more selective with internal capital while still participating in attractive innovation opportunities.

20. What Is the Finance Strategy of Teva?

Teva’s finance strategy has been shaped for years by the debt taken on in the 2016 Actavis Generics acquisition. As a result, the company’s financial priorities have been more conservative than those of a typical growth-oriented pharma company.

• Deleveraging remains central: Reducing debt and preserving liquidity have been recurring priorities in management communications.
• Cash generation matters as much as revenue growth: Teva needs growth that converts into cash, not just launches that add volume without margin.
• Capital allocation is selective: Management has emphasized targeted reinvestment in growth brands, pipeline assets, and high-return launches rather than large transformative deals.
• Margin improvement is part of the finance strategy: Better product mix, simplification, and disciplined spending are intended to expand earnings quality over time.
• Legacy liabilities remain relevant: Litigation-related cash obligations and compliance needs affect the room Teva has for more aggressive shareholder returns or M&A.

In practical terms, Teva’s finance strategy supports the broader corporate strategy by trying to create enough balance-sheet flexibility to fund growth brands and focused innovation without repeating the balance-sheet strain of the past decade.

21. What Major Acquisitions Has Teva Made?

Acquisitions have played a major role in Teva’s history, although the company’s recent posture has been more cautious and partnership-led than transformational.

Historically, M&A helped make Teva a global generics leader. More recently, the company has looked more focused on smaller partnerships, licensing, and portfolio discipline than on another large-scale acquisition program.

22. How Companies Like Teva Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in more than 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top firms. Companies like Teva use Umbrex when they need that level of strategy, operations, commercial, finance, ERP, technology, or AI talent, but do not need a full consulting team and its overhead. For a company with Teva’s mix of branded growth priorities, complex manufacturing, regulatory demands, and balance-sheet discipline, independent consultants can be especially useful for targeted, high-value initiatives.

• Growth-brand acceleration projects for AUSTEDO, AJOVY, or UZEDY, including launch diagnostics, patient-journey analysis, and sales-force effectiveness.
• Generic portfolio profitability reviews to identify which SKUs, dosage forms, and markets deserve more investment and which should be rationalized.
• Biosimilar market-entry strategy, including partner economics, launch sequencing, and channel access planning.
• Manufacturing-network and supply-chain optimization across internal plants, external suppliers, and API sourcing.
• Procurement and make-versus-buy strategy for critical inputs, especially where dual sourcing and resilience matter.
• Commercial-model redesign for specialty products, including market access, account management, and field-force deployment.
• Tender strategy and pricing analytics for Europe and international markets.
• Working-capital, cash-conversion, and deleveraging support tied to finance transformation priorities.
• Alliance-governance and integration support for licensing, biosimilar, or co-development partnerships.
• Targeted ERP, data, and AI projects in areas such as demand planning, quality analytics, pharmacovigilance workflows, and regulatory operations.